#USA #New York #Securities Fraud #Rosen Law Firm #Capricor

Capricor Therapeutics Class Action Overview

In the realm of securities fraud, investors often find themselves navigating complex legal waters. The recent case surrounding Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a pertinent example, as the Rosen Law Firm has opened avenues for affected investors to become deeply involved in a class action lawsuit. This opportunity is particularly crucial for purchasers of Capricor securities during the specified class period, which runs from October 9, 2024, to July 10, 2025.

Key Details of the Class Action

Why You Should Pay Attention

The Rosen Law Firm, a well-known player in the field of investor rights, emphasizes the importance of acting quickly. With a lead plaintiff deadline set for September 15, 2025, potential claimants are encouraged to step forward before this critical date. Those who acquired Capricor securities during the designated timeframe might be entitled to compensation without the burden of out-of-pocket expenses due to the contingency fee arrangement that the law firm offers.

Steps to Participate

Interested investors can join the class action by visiting Rosen Law Firm's submission page or by contacting attorney Phillip Kim at 866-767-3653. The law firm outlines that a class action lawsuit is already underway. Those wishing to act as lead plaintiffs must take legal action by the September 15 deadline. Essentially, the lead plaintiff serves as a key representative within the class, guiding the litigation process.

Importance of Choosing the Right Legal Representation

Choosing competent legal counsel is vital. The Rosen Law Firm’s reputation is built on its focus on securities class actions and shareholder derivative litigation, emphasizing the necessity for investors to work with firms that possess the appropriate experience and resources. Notably, Rosen Law Firm has been recognized for its successful track record in settling securities class action lawsuits, even setting records in the past. In 2019, they recovered upwards of $438 million for investors, proving their effectiveness in this challenging area.

Background of the Lawsuit

The lawsuit alleges that throughout the relevant period, Capricor's executives misled investors about their lead drug candidate, deramiocel, aimed at treating cardiomyopathy linked to Duchenne muscular dystrophy (DMD). Statements were made regarding the drug's safety and efficacy, including the anticipated Biologics License Application (BLA) from the FDA. However, these claims were countered by hidden adverse facts regarding the data from the Phase 2 HOPE-2 trials, which allegedly misled shareholders into purchasing inflated securities.

The Consequences of Misleading Statements

As the truth surrounding Capricor’s situation unfolded, it resulted in significant losses for investors who had acted on fraudulent information. The lawsuit captures the essence of these grievances, seeking accountability and recovery for the shareholders impacted by the deceptive practices of the company’s leadership.

Conclusion

For those who feel wronged by their investment in Capricor Therapeutics, now is the time to act. Engaging in this class action not only presents a chance to recover losses but also serves as a reminder of the importance of diligence when investing. With the September 15 lead plaintiff deadline fast approaching, interested participants should seek legal counsel, consider their options, and take appropriate steps to secure their interests in this unfolding situation. Stay informed by following updates from the Rosen Law Firm through their social media channels for ongoing developments pertaining to this class action lawsuit.